COGNICURRENT

The recent denial of a subsidy for the weight loss medication Wegovy raises questions about who can afford access to such costly treatments.

Novo Nordisk announced that the prices of popular weight loss drugs Ozempic and Wegovy will significantly decrease starting in 2027, with Wegovy becoming half as expensive and Ozempic a third less expensive for all patients.

Novo Nordisk announced a plan to reduce the price of its anti-obesity drug Wegovy by 50% in the U.S. starting in 2027 to improve affordability and competitiveness.

Novo Nordisk has announced a significant reduction in the list prices of its drugs, including Wegovy, Ozempic, and Rybelsus, effective January 2027.

Brazil's pharmaceutical retail sector generated approximately R$ 128.6 billion in 2025, bolstered by the popularity of weight-loss pens like Mounjaro, Ozempic, and Wegovy.

Novo Nordisk's new weight-loss drug, CagriSema, has been deemed 'obsolete' after disappointing clinical trials, leading to a significant drop in the company's shares.

The Swedish Dental and Pharmaceutical Benefits Agency has rejected a subsidy application for the obesity medication Wegovy from Novo Nordisk.

Recent discussions about the safety of weight loss medications, particularly GLP-1 receptor agonists like Wegovy and Ozempic, have emerged due to reports of pancreatitis in some users, prompting experts to clarify the actual risks involved.

The article debates the implications of relying on medications like Wegovy instead of promoting lifestyle changes for better health.

Anvisa, Brazil's health regulatory agency, is expected to make a decision in the coming weeks regarding the approval of two competitors to Ozempic and Wegovy, as the substance semaglutide loses its patent.

Boots is launching a new in-store service at 17 locations across the UK to provide weight loss injections after consultations with qualified pharmacists.

A reader shares their experience of losing weight using insoles as an alternative to the expensive weight loss drug Wegovy.

Many people using GLP-1 medications like Ozempic and Wegovy for weight loss are experiencing unexpected facial changes, causing concern despite their weight loss success.

Health experts warn that the rapid expansion of Ozempic and Wegovy for weight loss poses risks due to self-medication and misuse.

Novo Nordisk is preparing a response to the FDA over concerns regarding a misleading TV advertisement for its Wegovy weight-loss pill.

Novo Nordisk is preparing a response to the FDA regarding a letter that stated an advertisement for its Wegovy pill was misleading or false.

Hims & Hers has responded to Novo Nordisk's patent infringement lawsuit, calling it an attack on American consumers after launching a non-approved version of the drug Wegovy.

A new program in South Korea aims to provide free obesity treatment to patients with rare diseases and low-income individuals.

Novo Nordisk's stock surged approximately 8% following Hims & Hers's decision to withdraw a low-cost weight loss pill similar to Wegovy amid legal threats from both Novo Nordisk and the FDA.

Novo Nordisk's stock rose significantly after Hims and Hers announced they would not sell a generic version of Wegovy.

The American telehealth company Hims and Hers has decided to cease the sale of a copy of Novo's weight loss medication Wegovy after discussions with industry stakeholders.

The company Hims and Hers has ceased offering its cheaper copy of Novo Nordisk's weight loss medication Wegovy after constructive talks with stakeholders.

The company Hims and Hers has decided to stop offering a cheaper copy of Novo Nordisk's weight loss drug Wegovy.

The UK regulator MHRA warns that weight loss medications Ozempic and Wegovy may lead to sudden blindness due to a rare side effect called non-arteritic anterior ischemic optic neuropathy (NAION).

Medical experts have issued a warning to Ozempic and Wegovy users about a rare but serious sight issue that requires urgent treatment if experienced.

President Donald Trump's administration launched a website aimed at providing U.S. residents access to prescription medications at lower prices, featuring weight loss drug Wegovy and diabetes drug Ozempic.

US President Donald Trump has launched TrumpRx.gov, a platform offering up to 85% discounts on prescription medications, including weight loss products like Ozempic and Wegovy.

The daily summary highlights key events including Fachin's cancellation of a meeting to discuss the STF Code of Ethics, a request from Novo Nordisk for authorization to sell Wegovy in Brazil, and concerns over the health risks of mixing vodka and energy drinks during carnival.

Telehealth company Hims & Hers Health is launching a new weight-loss pill at $49 a month, competing directly with Novo Nordisk's Wegovy, which contains the same active ingredient.

Novo Nordisk criticizes Hims and Hers for planning to launch a copy of the weight loss drug Wegovy, claiming it poses significant risks to patient safety and threatens its intellectual property, prompting plans for legal action.

Novo Nordisk has issued a sharp condemnation of Hims and Hers for planning to launch a copy of the weight loss drug Wegovy, labeling it as illegal mass production that jeopardizes patient safety, and announcing intentions to take legal and regulatory action.

Danish pharmaceutical company Novo Nordisk's stock plummeted after the launch of a cheaper version of its Wegovy pill by US firm Hims and Hers.

Novo Nordisk has requested authorization from Anvisa to sell Wegovy in pill form in Brazil, with the request submitted on January 30, but the Brazilian regulatory agency has not yet responded.

Health authorities have issued a warning to users of weight loss medications like Mounjaro, Ozempic, and Wegovy due to reports of acute and chronic pancreatitis despite the lack of official confirmation linking these drugs to pancreatic inflammation.

11 patients are receiving compensation for the serious eye disease NAION due to the use of Novo Nordisk medications Wegovy and Ozempic, as revealed by new statistics from the Patient Compensation Association.

An increasing number of patients are receiving compensation for the serious eye disease NAION caused by the use of Novo Nordisk's drugs Wegovy and Ozempic, with 67 patients having sought compensation so far.

The article discusses the rapid return of weight after stopping the use of GLP-1 medications like Ozempic and Wegovy, highlighting concerns from medical professionals about their promotion as lifestyle solutions.

Novo Nordisk warns of a significant decline in revenue due to increased competition and low prices in the U.S. despite rising prescriptions for its new Wegovy pill.

Novo Nordisk, the maker of Wegovy and Ozempic, expects a significant revenue decline this year due to competition, patent expirations, and price reductions influenced by Donald Trump's policies.

Novo Nordisk's stock fell by up to 20% following a forecast predicting a significant decline in sales for its weight loss drugs Ozempic and Wegovy, resulting in a 13% revenue cut for 2026.

Novo Nordisk's shares fell 18% in Copenhagen following disappointing 2026 projections, signaling a challenging year for weight-loss market players despite previous optimism from strong sales of the Wegovy pill.

Novo Nordisk reported a revenue of over 309 billion kroner in 2025, marking a growth of six percent, though the growth in sales of weight loss drugs slowed in the fourth quarter, despite Wegovy sales exceeding expectations.

Novo Nordisk is facing a potential downturn as sales growth from weight loss drugs slowed, despite surpassing expectations with Wegovy sales reaching 21.9 billion kroner in the fourth quarter of 2025.

Novo Nordisk reported a revenue of just over 309 billion kroner in 2025 with a six percent growth, despite a slowdown in the sales growth of weight-loss drugs in the fourth quarter, although sales of the popular Wegovy still exceeded analysts' expectations.

Novo Nordisk has requested authorization from Anvisa to sell Wegovy in tablet form in Brazil, following its launch in the U.S.

Anvisa has approved the use of semaglutide for adults with established cardiovascular disease or obesity to reduce the risk of heart attack and stroke.

The UK Medicines and Healthcare products Regulatory Agency has warned of deaths linked to severe pancreatitis associated with weight-loss and diabetes medications such as Mounjaro and Wegovy, advising users to watch for intense and persistent abdominal pain.

New warnings have emerged about popular weight-loss medications like Ozempic and Wegovy, originally intended for diabetes treatment, highlighting potential rare side effects.

Users of weight loss pens, such as Mounjaro or Wegovy, should be aware of the rare but real possibility of developing acute pancreatitis, according to a warning from the UK's Medicines and Healthcare products Regulatory Agency (MHRA).

The FDA has requested pharmaceutical companies to remove warnings about potential suicidal thoughts from labels of common weight-loss medications, including Novo Nordisk's 'Wegovy' and Eli Lilly's 'Zyban', following a comprehensive review that found no link to such thoughts.